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Co-existence of a second primary malignancy in patients
with either ovarian or endometrial cancer
Zbigniew Studziƒski1, Zoran Stojcev2
O b j e c t i v e.  The aim of publication was the retrospectively analysis patients with ovarian and endometrial cancers at
which occurrence second primary malignancies were affirmed.
M a t e r i a l  a n d  m e t h o d s.  From 1989-1999 117 ovarian and 144 endometrial carcinomas have been evaluated and 33
multiple primary malignant neoplasms were detected. All double neoplasms have been histological recorded, doubtful cases
have been excluded. Coexistence of ovarian and endometrial carcinoma with second primary malignant neoplasm was
evaluated and controlled for age, parity, menarche age, last menstruation age, length of reproductive period, hypertension,
diabetes, body mass index, pelvic inflammatory disease (PID), grading, staging.
R e s u l t s.  Two primary cancers coexistence was found in 17 patients with ovarian tumour (14.3%) and in 16 patients with
endometrial tumour (11.2%). The most often prevalent neoplasm in both groups was breast cancer (5.1%) and (6.4%). In
the patients with ovarian cancer, breast cancer was found at much younger age than in patients with endometrial malignancy
(p=0.02). It was also observed that breast cancer diagnosis preceded that of ovarian cancer about 11.2 year average and about
3.2 year in women group with endometrial cancer.
Stomach cancer however, was diagnosed earlier at the group with endometrial cancer, than at the group with ovarian cancer,
and difference was statistically significant (p<0.001). At the group with endometrial cancer morbid obesity was observed
statistically significant more often (p=0.03) than at the group with ovarian cancer.
C o n c l u s i o n.  Patients with ovarian and endometrial carcinoma should be carefully and regularly followed up by monitoring
et every anatomic site, especially the breast, uterus, stomach, and bowel, in order that the development of a second primary
carcinoma can be detected as early as possible, and not be overlooked in examinations.
Analiza 33 przypadków wspólnego wyst´powania drugiego pierwotnego nowotworu z∏oÊliwego 
u chorych na raka jajnika i raka endometrium
C e l.  Celem pracy by∏a retrospektywna analiza pacjentek z rakiem jajnika oraz rakiem b∏ony Êluzowej macicy, u których
stwierdzono ponadto wyst´powanie drugiego pierwotnego nowotworu z∏oÊliwego.
M a t e r i a ∏  i m e t o d a.  Poddano analizie grup´ 117 chorych na raka jajnika oraz 144 pacjentek z rakiem endometrium,
leczonych w latach 1989-1999. U 33 pacjentek stwierdzono wyst´powanie drugiego pierwotnego nowotworu z∏oÊliwego.
Wspólne wyst´powania raka jajnika oraz raka endometrium z drugim pierwotnym nowotworem z∏oÊliwym oceniono pod
wzgl´dem takich czynników jak: wiek, rodnoÊç, wiek pierwszej i ostatniej miesiàczki, wyst´powanie nadciÊnienia t´tniczego,
cukrzycy, nadwagi, chorób zapalnych miednicy mniejszej, stopieƒ zró˝nicowania histologicznego i zaawansowania klinicznego
nowotworu.
W y n i k i.  Wspólne wyst´powanie dwóch pierwotnych nowotworów z∏oÊliwych stwierdzono u 17 pacjentek z rakiem jajnika
(14,3%) oraz u 16 kobiet z rakiem endometrium (11,2%). Najcz´stszym drugim nowotworem z∏oÊliwym w obu badanych
grupach chorych by∏ rak sutka (5,1%) i (6,4%). U pacjentek z rakiem jajnika nowotwór gruczo∏u piersiowego stwierdzano
znamiennie w m∏odszym wieku ani˝eli u chorych na raka endometrium (p=0,02). Zaobserwowano ponadto, ˝e rozpoznanie
raka sutka poprzedza∏o Êrednio o oko∏o 11,2 lat wykrycie raka jajnika oraz o 3,2 lat w grupie kobiet leczonych z powodu raka
endometrium. Natomiast wyst´powanie raka ˝o∏àdka wczeÊniej stwierdzano u chorych na raka endometrium ani˝eli
u pacjentek z rakiem jajnika i by∏a to zale˝noÊç znamienna statystycznie (p<0,001). Stwierdzono ponadto, ˝e statystycznie
znamiennie cz´Êciej (p=0,03) obserwowano olbrzymià oty∏oÊç u chorych na raka endometrium ze wspó∏istnieniem drugiego
nowotworu, ani˝eli w analogicznej grupie kobiet chorych na raka jajnika.
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Introduction
Multiple primary malignancies have been divided into
two sub-groups. The term metachronic tumours is used
for primary malignancies which appear within six months
or more of one another. Synchronic tumours appear
simultaneously or are recognized within a period shorter
than six months [1]. Among the reasons for multiple
malignancies those recognized as the most common
include genetic defects, disturbancies of the immuno-
logical system, exposure to environmental carcinogens
and the effects of previous oncolytic treatment [1, 2]. In
women with either ovarian or endometrial cancer meta-
chronic or synchronic cancers of the breast, the stomach
and the colon are significantly more common. One may
also observe a reversal of this situation – i.e. in women
with breast cancer or colorectal cancer the likelihood
of developing endometrial cancer, ovarian cancer or
breast cancer is increased [3]. The best documented
genetic defect associated with endometrial cancer is
the Lynch II syndrome. The Lynch II syndrome is
a subgroup of Hereditary Non Polyposis Colorectal
Cancer in which colorectal cancer, endometrial cancer
and breast cancer are inherited acc. to the autosomal,
dominant pattern [4-7]. Among the multiple malignancy
syndromes associated with ovarian cancer arising from
genetic defects the most common is the breast
cancer/ovarian cancer syndrome [8, 9]. Therefore, every
female patient reporting with one of the listed
malignancies must undergo careful scrutiny for possible
associated tumours, both during initial diagnosis and in
the follow-up period. Before the treatment course is
decided these patients should also undergo additional
examination – abdominal ultrasound, mammography,
colonoscopy, computed tomography and contrast X-Ray
of the gastrointestinal tract.
Material
We have analyzed 261 women undergoing surgical treatment at
the Dept. of Gynaecology and Obstetrics of the Regional
Specialist Hospital in S∏upsk. 117 of these patients were treated
for ovarian cancer and 144 for endometrial cancer. Altogether in
33 patients we observed the co-existence of two primary
neoplasms – 17/117 with ovarian cancer (OC) and 16/144 with
endometrial cancer (EC). The pathological specimens were
examined by the same doctor at the pathology Dept. of the
Regional Specialist Hospital in S∏upsk. In those cases when
a second primary tumour was diagnosed the samples were
reexamined in order to rule out metastases or recurrence of
the initial malignancy. In every case the second primary tumour
was found before the diagnosis of ovarian or endometrial
cancer or during the surgical treatment for these two malig-
nancies. No patient developed a second malignancy during
follow-up.
For the purpose of further analysis the patients with two
co-existing primary tumours were divided into two groups: (1) 16
patients with ovarian cancer and a co-existing second malignancy
and (2) 17 patients with ovarian cancer and a co-existing second
malignancy. We analyzed the following parameters: mean age,
number of births/miscarriages; mean age of second primary
cancer diagnosis; the time of the first and last menstruation;
duration of the reproductive period; obesity, arterial hyper-
tension; diabetes; presence of uterine myomas, endometriosis;
diagnosis of malignancy among first degree relatives; the grade
of histological differentiation; degree of clinical advancement
acc. to FIGO.
Method
Throughout the statistical analysis we applied the following
methods: group (1) estimation – estimators of mean probability,
standard deviation; in group (2) hypothesis verification – chi-
square test, Student’s T-test. Differences were assumed to be
statistically significant when p=0.05.
Results
The analysis of the co-existence of a second primary
malignancy was performed on 117 women with ovarian
cancer (OC) and 144 women with endometrial cancer
(EC). In the OC group a second primary malignancy was
found in 17 pts. (14.45), while in the EC group it was
found in 16 pts. (11.2%). Altogether we observed 33 cases
of co-existent second primary malignancy – all of them
synchronous. In the OC group the most common second
malignancy was breast cancer – diagnosed in 6 pts.
(5.1%). Breast cancer was also the most common second
malignancy in the EC group, where it was found in 9
cases (6.4%). A detailed presentation of the frequency of
different types of second primary malignancies appears in
Table I.
The mean age of ovarian cancer diagnosis in the OC
group was 59.4 yrs, while for endometrial cancer diagnosis
in the EC group it was 60.2 yrs and did not show
a statistically significant difference (p=0.81). Table II
presents the mean age of the patients at the time of
diagnosis of the second primary malignancy. We found
that breast cancer as the second primary malignancy
affected (p=0.02) younger patients (p=0.02) in the OC
group (48.2 yrs) than in the EC group (57.0 yrs). On the
contrary, gastric cancer appeared in younger patients
from the EC group as compared to the OC group,
reaching statistical significance (p<0.001).
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W n i o s k i.  Pacjentki chore na raka jajnika i raka b∏ony Êluzowej macicy powinny byç szczególnie uwa˝nie badane pod kàtem
wyst´powania drugiego pierwotnego nowotworu z∏oÊliwego. Dotyczy to szczególnie takich narzàdów jak sutek, ˝o∏àdek
i jelito, tak, by rozwój drugiego nowotworu móg∏ zostaç jak najwczeÊniej rozpoznany.
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Table II. Mean age at diagnosis of second primary malignancy
in patients with ovarian cancer and endometrial cancer
Mean age [yrs.] Mean age [yrs.]
Breast cancer 57.0 48.2
Colorectal cancer 51.5 55.5
Cervical cancer 47.0 50.5
Gastric cancer 55.0 81.0
Gall bladder cancer (-) 55.0
Arterial hypertension was observed in 38% of
patients in the EC group and in 24% of patients in the
OC group (p=0.38); while diabetes – in 12% and 6% of
patients, respectively (p=0.51).
For the body mass analysis the patients were further
divided into three subgroups depending on the calculated
body mass index (BMI) – group 1 with correct body mass
(BMI 19-24); group 2 – obese patients (BMI 25-32) and
group 3 – with extreme obesity (BMI>32). After cal-
culations we assigned 25% of patients with EC and 47%
of patients with OC to group I; group II encompassed
13% of patients with EC and 35% of patients with OC;
group III consisted of 62% of patients from the EC group
and of 18% of patients from the OC group. Among
patients from the EC group who developed a second
primary carcinoma extreme obesity was statistically
significantly more common than in the analogous group
of patients from the OC group.
The mean number of childbirths was the same in
the OC and the EC group – 2.5 per woman. In the EC
group non-parturients accounted for 19% of pts; women
who gave birth 1-2 times – 44%, and women who had
over 2 childbirths – 37%. In the OC group the same
figures were 12%; 35% and 53%, respectively. The
differences between the number of childbirths did not
reach statistical significance (p=0.65). The mean number
of miscarriages was 0.7 in the EC group and 0.8 in the OC
group and failed to reach statistical significance (p=0.75).
The mean age of first menstruation was 13.8 in the EC
group and 14.4 in the OC group and also failed to reach
statistical significance (p=0.21). The mean age of the last
menstruation was 50.7 yrs. in the EC group and 49.1 yrs.
in the OC group and failed to reach statistical significance
(p=0.27). We discerned no statistically significant
difference between the entire duration of the reproductive
period (36.9 in the EC group; 34.7 in the OC group;
p=0.11). Detailed family history revealed malignancies in
first degree relatives of 17% of women from the EC
group and in 6% of women in the OC group.
Pelvic inflammatory diseases (PID) were reported
by 6% of women from the OC group and by no women
from the EC group (p=0.32). Myomas of the uterus were
found in 25% of patients with EC and in no patients with
OC, the difference reaching statistical significance
(p=0.003). Endometriosis was present in 12% of patients
with EC and in no patients with OC (p=0.13).
An analysis of EC patients who had developed
a second malignancy revealed stage I of clinical advan-
cement in 62% of patients, stage II in 19% of patients,
stage III in 19% of patients; there were no patients in
stage IV.
In an analogous analysis of the OC patients we found
stage I of clinical advancement in 6% of patients, stage II
in 18% of patients, stage III in 36% of patients; there
also were no patients in stage IV.
More advanced stages of advancement were
statistically significantly more common in patients with
ovarian cancer (p=0.001).
In EC patients histopathological stage G1 was found
in 88% of patients, G2 in 6% and G3 in 6% of patients
while in OC patients histopathological stage G1 was
found in 59% of patients, G2 in 24% and G3 in 17% of
patients, failing to reach statistical significance (p=0.18).
Discussion
Many authors report that patients with ovarian cancer
and endometrial cancer are at a higher risk of developing
cancer of the breast and cancer of the colon, and vice
versa [10-12]. Shinohara et al [13], having analyzed 316
patients with primary malignancies of the female genitary
system have found 17 cases of concomitant second
malignancy. The most common of these was colorectal
cancer (5 cases) and breast cancer (4 cases). Having
examined 25 605 women Delin et al [14] have reported
that EC was present in 5% of cases while the concomitant
appearance of numerous malignancies was in 9% of cases
associated with EC. In 44% of women with more than
one malignancy associated with EC they discerned
a familial trait of cancer. Schunemann [15] observed
163 cases of a secondary malignancy (11%) among
1503 women with EC; in 60% of cases this secondary
malignancy was breast cancer while in 1% of cases the
patients developed two secondary malignancies. Similar
observations have been made by Bucy et al [16] – among
266 patients with EC they discerned 12% of cases of
a secondary malignancy, mostly breast cancer.
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Table I. Secondary primary malignancy in patients with ovarian
cancer and endometrial cancer
number % number % number
Breast cancer 9 6.4 6 5.1 15
Colorectal cancer 2 1.4 2 1.7 4
Cervical cancer 1 0.7 2 1.7 3
Gastric cancer 1 0.7 1 0.8 2
Gallbladder cancer 0 0 2 1.7 2
Endometrial cancer 0 0 2 1.7 2
Ovarian cancer 2 1.4 0 0 2
Cancer in endometriosis 1 0.7 0 0 1
Melanoma of the mandible 0 0 1 0.8 1
Lymphogranulomatosis 
maligna 0 0 1 0.8 1
Total 16 11.3 17 14.3 33
Bokhman et al [17], having retrospectively analyzed
the cases of 5450 women with primary breast cancer have
pronounced the risk of concomitant EC to be 13.9 times
higher than in the general population. In a group of 1400
women with EC the risk of developing breast cancer as
a secondary malignancy was 9 times higher than in the
general population. Prospective studies performed on
481 patients with EC have shown 1.9% of concomitant
breast cancer (19 times more common than in the control
group). In a similar study of 318 women with breast
cancer EC was found in 2.4% of women (6 times more
often than in the control group) and OC in 1.3% of
women. Ayhan et al [18] have analyzed the cases of 29
patients who presented with concomitant malignancies
of the female genitary system. The most common co-
existence of malignancies was that of OC and EC – 51.7%
of patients, with a 5-year survival of 73.3%. Auranen et al
[10] evaluated women with concomitant OC and breast
cancer and found, that if the first diagnosed malignancy
was breast cancer the mean age at diagnosis was statis-
tically significantly lower (50 yrs.) than in patients in
whom breast cancer was the only diagnosed malignancy
(61.1 yrs.). Such relations were not observed when the
primary malignancy was OC. Women who developed
ovarian cancer and then breast cancer were of the same
age at initial diagnosis (62.2 yrs.) as women with ovarian
cancer only (61.1 yrs.). In our study material breast cancer
was diagnosed at a significantly younger age than ovarian
cancer (approx. 11.2 years earlier) and some 3.2 yrs earlier
than endometrial cancer; achieving statistical significance
(p=0.02). Suris-Swartz et al [19] report that women who
developed breast cancer at an age of below 50 yrs have
a 4.3 higher risk of developing ovarian cancer, as
compared to women who developed breast cancer at an
age of over 50 yrs. On the other hand in women with
ovarian cancer who had developed the malignancy at an
age of less than 50 yrs the risk of developing breast cancer
as a second malignancy is 0.6, as compared to women
who had developed ovarian cancer at an age of more
than 50 yrs. Falkenberry et al [20] have performed an
analysis of 22 women with concomitant OC and EC and
report that these patients are generally younger than
women who develop either EC or OC as a sole
malignancy. These results have found no confirmation
in previously published papers on EC [3, 4] nor in our
present material. Franceschi et al [21] have found that
late menopausal age is a risk factor of the development of
OC. The relative risk ratio for women who became
menopausal before 44 yrs of age, between 45 and 52 yrs
and over 52 yrs is 1.4, 1.6 and 1.9, respectively. An analysis
of our data has shown that later menopause increases
the risk of developing a secondary malignancy, especially
breast cancer, EC and cancer of the colon [12]. In our
study BMI was pronounced as an important risk factor for
developing concomitant EC and breast cancer. We have
also found that women with EC had a significantly higher
BMI than women with OC. Our earlier analysis [12]
concerning the co-existence of EC with a second primary
malignancy has shown that women with BMI > 32 were
at en extensive risk of such a clinical situation.
Conclusions
1. The co-existence of a second primary malignancy is
similar among patients with ovarian cancer and
endometrial cancer.
2. In women with ovarian cancer and endometrial cancer
the most common second malignancy was breast
cancer.
3. Patients with co-existent ovarian cancer and breast
cancer developed breast cancer at a significantly earlier
age than patients with co-existent endometrial cancer
and breast cancer.
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